Menu
Innovation Observatory > Reports > Drugs > Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis – after DMARD failure

< Back

Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis – after DMARD failure

Drugs

Musculoskeletal

October 2017


There is currently no cure for rheumatoid arthritis. The most common treatment options are steroids to reduce inflammation, medications to reduce pain and inflammation and medications that slow the progression of joint damage from RA. Tocilizumab is already licensed for the treatment of RA as both intravenous and subcutaneous (pre-filled syringe) formulations, however its use, via an auto-injector device is being developed. This is expected to improve the ease of patients treating themselves, in those who have active moderate to severe RA who do not respond to some conventional treatments.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

15053-Tocilizumab-RoACTEMRA-for-adults-with-rheumatoid-arthritis



Load More Related Posts
Get Alerts